(Q44888158)

7 December 2017

title

Higher cross-subtype IFN-γ ELISpot responses to Gag and Nef peptides in Brazilian HIV-1 subtype B- and F1- than in C-infected subjects (English)

1 reference

7 December 2017

6

Beatriz Grinsztejn

1 reference

7 December 2017

2

Gonzalo Bello

1 reference

7 December 2017

Mariza Gonçalves Morgado

9

object named as

Mariza Gonçalves Morgado

1 reference

Monick Lindenmeyer Guimarães

7 December 2017

5

object named as

Monick Lindenmeyer Guimarães

1 reference

7 December 2017

author name string

Fernanda Heloise Côrtes

1

1 reference

7 December 2017

Carla Vorsatz

3

1 reference

7 December 2017

José Henrique Pilotto

4

1 reference

7 December 2017

Valdiléa Gonçalves Veloso

7

1 reference

7 December 2017

Aguinaldo Roberto Pinto

8

1 reference

7 December 2017

language of work or name

English

0 references

publication date

20 December 2012

1 reference

7 December 2017

1 reference

7 December 2017

volume

31

1 reference

7 December 2017

issue

7

1 reference

7 December 2017

page(s)

1106-1112

1 reference

Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

Viral evolution and escape during acute HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

Prospects for an AIDS vaccine: three big questions, no easy answers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

Evolutionary and immunological implications of contemporary HIV-1 variation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

Molecular epidemiology of HIV-1 in Brazil: high prevalence of HIV-1 subtype B and identification of an HIV-1 subtype D infection in the city of Rio de Janeiro, Brazil. Evandro Chagas Hospital AIDS Clinical Research Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

Molecular Epidemiology of HIV Type 1 in Northern Brazil: Identification of Subtypes C and D and the Introduction of CRF02_AG in the Amazon Region of Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

Moderate prevalence of transmitted drug resistance and high HIV-1 genetic diversity in patients from Mato Grosso State, Central Western Brazil.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

HIV-1 genetic diversity and drug resistance among treatment naïve patients from Southern Brazil: An association of HIV-1 subtypes with exposure categories

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

Prevalences, genotypes, and risk factors for HIV transmission in South America.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

Analysis of HIV type 1 diversity in pregnant women from four Latin American and Caribbean countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

Epidemiological and molecular characteristics of HIV-1 infection among female commercial sex workers, men who have sex with men and people living with AIDS in Paraguay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

Diversity considerations in HIV-1 vaccine selection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

Consensus and Ancestral State HIV Vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

Minimization of genetic distances by the consensus, ancestral, and center-of-tree (COT) sequences for HIV-1 variants within an infected individual and the design of reagents to test immune reactivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

Profile of T cell recognition of HIV type 1 consensus group M Gag and Nef peptides in a clade A1- and D-infected Ugandan population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

Ancestral and consensus envelope immunogens for HIV-1 subtype C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

Increased detection of HIV-specific T cell responses by combination of central sequences with comparable immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

Group M-based HIV-1 Gag peptides are frequently targeted by T cells in chronically infected US and Zambian patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

Intra- and inter-clade cross-reactivity by HIV-1 Gag specific T-cells reveals exclusive and commonly targeted regions: implications for current vaccine trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

Analysis of the distribution of HLA-B alleles in populations from five continents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

The analysis of near full-length genome sequences of human immunodeficiency virus type 1 BF intersubtype recombinant viruses from Chile, Venezuela and Spain reveals their relationship to diverse lineages of recombinant viruses related to CRF12_BF.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

Simplified strategy for detection of recombinant human immunodeficiency virus type 1 group M isolates by gag/env heteroduplex mobility assay. Study Group on Heterogeneity of HIV Epidemics in African Cities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

HIV type 1 env subtype A variants in Taiwan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

Sequences and phylogenetic analysis of the nef gene from Thai subjects harboring subtype E HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) Software Version 4.0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

Cross-clade reactivity of HIV-1-specific T-cell responses in HIV-1-infected individuals from Botswana and Cameroon.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus type 1 non-B clades (A to G): importance of HLA anchor residue conservation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

Cytolytic T lymphocytes (CTLs) from HIV-1 subtype C-infected Indian patients recognize CTL epitopes from a conserved immunodominant region of HIV-1 Gag and Nef

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

High degree of inter-clade cross-reactivity of HIV-1-specific T cell responses at the single peptide level.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

Cross-Clade CD8+ T-Cell Responses With a Preference for the Predominant Circulating Clade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

Magnitude, breadth, and functional profile of T-cell responses during human immunodeficiency virus primary infection with B and BF viral variants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

Human immunodeficiency virus type 1 neutralization by plasma from B or F genotype infected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

Individual HIV type 1 envelope-specific T cell responses and epitopes do not segregate by virus subtype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.023

10.1016/J.VACCINE.2012.12.023

7 January 2021

Identifiers

DOI

1 reference

7 December 2017

1 reference